Details

Autor(en) / Beteiligte

• Lee, Myungsun
• Lee, Jongseok
• Carroll, Matthew W
• Choi, Hongjo
• Min, Seonyeong
• Song, Taeksun
• Via, Laura E
• Goldfeder, Lisa C
• Kang, Eunhwa
• Jin, Boyoung
• Park, Hyeeun
• Kwak, Hyunkyung
• Kim, Hyunchul
• Jeon, Han-Seung
• Jeong, Ina
• Joh, Joon Sung
• Chen, Ray Y
• Olivier, Kenneth N
• Shaw, Pamela A
• Follmann, Dean
• Song, Sun Dae
• Lee, Jong-Koo
• Lee, Dukhyoung
• Kim, Cheon Tae
• Dartois, Veronique
• Park, Seung-Kyu
• Cho, Sang-Nae
• Barry, Clifton E

Titel

Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis

Ist Teil von

• The New England journal of medicine, 2012-10, Vol.367 (16), p.1508-1518

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• There are limited therapeutic options for extensively drug-resistant tuberculosis. In this study from South Korea, linezolid was shown to have some activity in treating resistant tuberculosis; however, its use was associated with clinically significant toxicity. Linezolid (Zyvox, Pfizer) was approved in 2000 for drug-resistant, gram-positive bacterial infections. 1 A member of the oxazolidinone antibiotic class, linezolid inhibits protein synthesis by binding the 23S ribosomal RNA (rRNA) portion of the bacterial 50S ribosomal subunit. 2 In adults, linezolid is administered at a dose of 600 mg twice daily, with phase 3 and postmarketing trials showing an acceptable side-effect and adverse-event profile during the FDA-approved 28 days of therapy. 3 Data on longer-term use are limited, but serious neuropathies (e.g., peripheral and optic neuropathies), myelosuppression, and hyperlactatemia have been observed 4 , 5 and are considered to be related to the inhibition . . .